Two supplements are sold for liver health: milk thistle, which has decades of clinical studies and a long history of traditional use, and N-acetylcysteine (NAC), a compound most pharmacologists know from acetaminophen overdose treatment but now appearing in many antioxidant products. Both have plausible mechanisms. Both have randomized trials behind them. Neither delivers quite what the label says - and the dose details matter much more than most product pages mention.
Silymarin: what is actually in a milk thistle supplement
Milk thistle (Silybum marianum) seeds contain flavanolignans known collectively as silymarin. The term silymarin on a supplement label does not mean the whole plant - it refers to a standardized extract, predominantly silybin, silychristin, and silydianin. That distinction matters because crude milk thistle seed powder and a standardized silymarin extract are not interchangeable, and researchers ran most of the meaningful trials using the latter.
The largest placebo-controlled US trial, published in JAMA Internal Medicine in 2012, randomized 154 patients with chronic hepatitis C who didn't respond to antiviral treatment. Participants received 420 mg of silymarin three times daily, 700 mg three times daily, or matched placebo for 24 weeks. Neither dose reduced serum alanine aminotransferase levels compared to placebo - the primary endpoint - and the trial authors concluded that high-dose silymarin didn't help this group.
The NASH trials and the enzyme signal
A second major trial - the SyNCH study, published in 2019 - tested a proprietary standardized preparation (Legalon®) at 420 mg and 700 mg three times daily over 48 weeks in patients with non-alcoholic steatohepatitis (NASH) without cirrhosis. The primary endpoint was histological improvement of at least two points on the NASH Activity Score. Neither dose met that endpoint. The authors noted an unexpected placebo effect on fibrosis, which made it hard to interpret results - a reminder of how hard it is to run clean liver histology trials.
A 2023 systematic review that pooled data from multiple trials reached a more encouraging conclusion: silymarin supplements led to statistically significant reductions in ALT and AST across different chronic liver disease populations. The improvements were modest, and the review noted differences across study populations, preparations, and doses. Still, enzyme reduction is the most consistent result silymarin has shown in human trials.
NIH's LiverTox database - a peer-reviewed resource tracking hepatotoxicity evidence for clinically used substances - describes milk thistle human trial data as promising but not conclusive, which is about as honest a summary as the field allows.
Dose and standardization: the detail most labels skip
If the trial evidence is your starting point, the doses actually studied matter. The major US trials used 420 mg to 700 mg of standardized silymarin extract per dose, three times daily - yielding 1,260 mg to 2,100 mg per day total. A product that lists milk thistle seed powder without saying what percent is silymarin uses a form that wasn't tested in those trials and might have only a fraction of the active compounds at the dose on the label.
The NIH StatPearls review of milk thistle notes that standardization and quality control vary a lot across commercial products - which helps explain why smaller studies with unspecified preparations produce different results. This is not a problem unique to milk thistle. Absorption and form affect what a supplement actually delivers across most botanical categories. Our piece on collagen absorption and why source form matters as much as the dose explains the same problem in a different ingredient.
NAC: a different mechanism, a more targeted track record
N-acetylcysteine (NAC) comes from the amino acid cysteine and is a precursor to glutathione - the liver's main antioxidant inside cells. Doctors use IV NAC for acetaminophen overdose - it quickly replenishes glutathione and prevents liver damage. That evidence is strong, mostly from IV use, so don't assume oral supplements work the same way at lower doses in normal situations.
For metabolic liver disease, the most targeted recent trial - a double-blind, randomized, placebo-controlled study in patients with metabolic dysfunction-associated steatotic liver disease (MASLD, what researchers now call instead of NAFLD) - assigned 69 participants to either 600 mg of NAC three times daily (1,800 mg/day total) or placebo for eight weeks. The NAC group showed significant reductions in fasting insulin, HOMA-IR, and C-reactive protein, along with increased total glutathione levels - but no statistically significant change in hepatic steatosis grade, ALT, or AST compared to placebo.
That mixed result is worth noting. NAC at 1,800 mg/day shifted metabolic and antioxidant markers but not liver enzymes or imaging, which is what doctors actually use. We don't know if longer use or a different dose would change the results; the trial authors called for follow-up investigation.
NAC in drug-induced liver injury: a related but separate body of evidence
For context: NAC also helps with drug-induced liver injury beyond acetaminophen. A review in Molecules found that NAC reduced injury markers across multiple drug-induced liver injury scenarios, by replenishing glutathione and reducing inflammation. This applies to different patients in different situations, not to metabolic liver disease or general health prevention. But it does explain why doctors use NAC in liver medicine and why scientists are interested in oral supplements.
What the dosing evidence actually tells you
Read together, the human trial data on both compounds points to a few honest conclusions:
- Researchers tested silymarin at 420 mg to 700 mg three times daily in well-designed trials and found it didn't improve liver enzymes or imaging in chronic hepatitis C and NASH patients. When researchers combined results, they found a modest link to lower liver enzymes across different liver diseases.
- NAC at 600 mg three times daily for eight weeks may help metabolic markers (insulin, inflammation, glutathione) in MASLD patients, but doesn't improve liver structure or enzymes in that time.
- In both cases, the product's purity and form determine if what you're taking matches what was tested. The dose and preparation on the label need to match the trial conditions before any comparison is meaningful.
For how timing and duration change what the evidence supports, see the Ayurnomics piece on zinc dosing windows and why timing changes outcomes - it explains this in a different area.
If you are managing a liver condition under clinical care, or taking medications that the liver processes, the potential for herb-drug interactions - particularly silymarin's reported effects on certain cytochrome P450 enzymes - means you should talk to your doctor before adding either compound at the doses described here.
More from the science journal, including evidence-reviewed ingredients across the liver and metabolic health space, is in our Liver and Detox collection.
Want more like this? Join the Inner Circle for one considered piece every Sunday.